Plan D: Experts predict government savings, but higher co-pays with Trump plan for lowering drug pricesMay 21, 2018
The White House's strategy calls for moving expensive treatments from under Medicare Part B to Medicare Part D.
For one of President Trump's proposals for lowering the cost of drugs, the path to implementation could be long.
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Ketchum, Ogilvy, Porter Novelli, Weber Shandwick, and FleishmanHillard are among the firms that have been awarded past Centers for Medicare and Medicaid Services IDIQ accounts.
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick
Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
Susannah Fox is the former chief technology officer for HHS.